Abstract: ROS1  fusion is a common genetic alteration in non-small-cell lung cancer. Crizotinib, an anaplastic lymphoma kinase inhibitor, shows efficacy in the treatment of lung cancer cases with ROS1  translocation. We report the response to crizotinib of a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1  fusion variant, which was different from the two common SLC34A2-ROS1  fusion types reported in the literature. After crizotinib administration, overall recovery was good in this patient; the primary lesion was successfully treated, the lymph node metastases had disappeared, and the metabolism was normal.
Keywords: SLC34A2-ROS1  fusion, crizotinib, lung adenocarcinoma, next-generation sequencing

摘要视频链接：Crizotinib treatment in lung adenocarcinoma patient with ROS1 fusion